Literature DB >> 25410224

General aspects of diabetes mellitus.

Uazman Alam1, Omar Asghar2, Shazli Azmi2, Rayaz A Malik3.   

Abstract

Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycemia due to an absolute or relative deficit in insulin production or action. The chronic hyperglycemia of diabetes mellitus is associated with end organ damage, dysfunction, and failure, including the retina, kidney, nervous system, heart, and blood vessels. The International Diabetes Federation (IDF) estimated an overall prevalence of diabetes mellitus to be 366 million in 2011, and predicted a rise to 552 million by 2030. The treatment of diabetes mellitus is determined by the etiopathology and is most commonly subdivided in type 1 and type 2 diabetes mellitus. There is a greater propensity towards hyperglycemia in individuals with coexisting genetic predisposition or concomitant drug therapy such as corticosteroids. The screening for diabetes mellitus may either be in the form of a 2hour oral glucose tolerance test, or via HbA1c testing, as recently recommended by the American Diabetes Association (ADA). Strong associations have been shown in observational studies suggesting poor clinical outcomes both with chronic hyperglycemia and acutely in intensive care settings. However, tight glycemic control in this setting is a contentious issue with an increased incidence of hypoglycemia and possible increase in morbidity and mortality. In a critically ill patient a glucose range of 140-180mg/dL (7.8-10.0mmol/L) should be maintained via continuous intravenous insulin infusion.

Entities:  

Keywords:  Diabetes mellitus; MODY; inpatient glycemic control; type 1 diabetes mellitus; type 2 diabetes mellitus; variable rate insulin infusion

Mesh:

Substances:

Year:  2014        PMID: 25410224     DOI: 10.1016/B978-0-444-53480-4.00015-1

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  41 in total

1.  A free-energy landscape for the glucagon-like peptide 1 receptor GLP1R.

Authors:  Raphael Alhadeff; Arieh Warshel
Journal:  Proteins       Date:  2019-08-02

2.  National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.

Authors:  Jisu Kim; Susin Park; Hyunsoo Kim; Nam Kyung Je
Journal:  Eur J Clin Pharmacol       Date:  2019-09-02       Impact factor: 2.953

3.  Uncoupling Protein 2 Inhibition Exacerbates Glucose Fluctuation-Mediated Neuronal Effects.

Authors:  Susana Cardoso; Raquel M Seiça; Paula I Moreira
Journal:  Neurotox Res       Date:  2017-09-05       Impact factor: 3.911

4.  Downregulation of miR-17 suppresses TGF-β1-mediated renal fibrosis through targeting Smad7.

Authors:  Haixia Fu; Debo Chu; Xiuli Geng
Journal:  Mol Cell Biochem       Date:  2021-04-02       Impact factor: 3.396

5.  Resolvin D5 disrupts anxious- and depressive-like behaviors in a type 1 diabetes mellitus animal model.

Authors:  Felipe Fagundes Leão; Ana Paula Farias Waltrick; Waldiceu Aparecido Verri; Joice Maria da Cunha; Janaina Menezes Zanoveli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-07-19       Impact factor: 3.195

6.  Abnormal glucose regulation in Chinese patients with coronary artery disease: a gender analysis.

Authors:  Juan Liu; Li-Qun He; Wei Zhu; Gang-Feng Duan; Yong Fang; Ying Feng; Li-Qun Tian; Qiong-Li Zheng
Journal:  J Cardiothorac Surg       Date:  2022-05-03       Impact factor: 1.522

Review 7.  Astragalin: A Bioactive Phytochemical with Potential Therapeutic Activities.

Authors:  Ammara Riaz; Azhar Rasul; Ghulam Hussain; Muhammad Kashif Zahoor; Farhat Jabeen; Zinayyera Subhani; Tahira Younis; Muhammad Ali; Iqra Sarfraz; Zeliha Selamoglu
Journal:  Adv Pharmacol Sci       Date:  2018-05-02

Review 8.  The role of KATP channels in cerebral ischemic stroke and diabetes.

Authors:  Vivian Szeto; Nai-Hong Chen; Hong-Shuo Sun; Zhong-Ping Feng
Journal:  Acta Pharmacol Sin       Date:  2018-04-19       Impact factor: 6.150

9.  Leu72Met polymorphism of GHRL gene decreases susceptibility to type 2 diabetes mellitus in a Mexican population.

Authors:  Edgar Alfonso Rivera-León; Mara Anaís Llamas-Covarrubias; Sergio Sánchez-Enríquez; Erika Martínez-López; Mercedes González-Hita; Iris Monserrat Llamas-Covarrubias
Journal:  BMC Endocr Disord       Date:  2020-07-22       Impact factor: 2.763

10.  Gene polymorphisms of Patatin-like phospholipase domain containing 3 (PNPLA3), adiponectin, leptin in diabetic obese patients.

Authors:  Omnia Aly; Hanan Hassan Zaki; Mohamed R Herzalla; Ahmed Fathy; Nermin Raafat; Mohamed M Hafez
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.